Monoclonal antibody · developed by argenx
Empasiprubart (ARGX-117) is an agent given intravenously or by subcutaneous autoinjector. It is studied in multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07091630 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | ARGX |
| NCT06742190 | Phase 3 | Multifocal Motor Neuropathy (MMN) | Active not recruiting | ARGX |
| NCT05405361 | Phase 2 | Multifocal Motor Neuropathy (MMN) | Active not recruiting | ARGX |
| NCT07612020 | Phase 1 | Healthy Volunteers | Recruiting | ARGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDPHealthy VolunteersMMNMultifocal Motor Neuropathy (MMN)
Updated Oct 11, 2026. Something wrong or missing? Report it on the ARGX page.
See ARGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARGX catalysts and pipeline →